Accepted for Publication: September 6, 2020.
Published Online: November 16, 2020. doi:10.1001/jamainternmed.2020.6084
Corresponding Author: Lindsey C. Yourman, MD, Division of Geriatrics and Gerontology, School of Medicine, University of California, San Diego, 9500 Gilman Dr, MC 0665, Central Research Services Facility, Third Floor, Cubicle 331, La Jolla, CA 92107 (lyourman@health.ucsd.edu).
Author Contributions: Drs Yourman and Lee had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Yourman, Smith, Schonberg, Schoenborn, Widera, Rodriguez, Lee.
Acquisition, analysis, or interpretation of data: Yourman, Cenzer, Boscardin, Nguyen, Schoenborn, Orkaby, Rodriguez, Lee.
Drafting of the manuscript: Yourman, Schonberg, Rodriguez, Lee.
Critical revision of the manuscript for important intellectual content: Yourman, Cenzer, Boscardin, Nguyen, Smith, Schoenborn, Widera, Orkaby, Lee.
Statistical analysis: Cenzer, Boscardin, Rodriguez.
Obtained funding: Schonberg, Lee.
Administrative, technical, or material support: Yourman, Nguyen, Widera, Lee.
Supervision: Yourman, Smith, Lee.
Conflict of Interest Disclosures: Dr Yourman reported receiving grant 1TL1TR001443-01 from the National Institutes of Health (NIH) National Center for Advancing Translational Sciences during the conduct of the study. Dr Schonberg reported receiving grant R01CA181357 from the National Cancer Institute during the conduct of the study. Dr Schoenborn reported receiving grants from National Institute on Aging (NIA) outside the submitted work. Dr Orkaby reported receiving grants from the Department of Veterans Affairs (VA) and the NIA/NIH, during the conduct of the study. Dr Lee reported receiving grants from the NIH and VA Health Services Research and Development (HSR&D) during the conduct of the study. No other disclosures were reported.
Funding/Support: This project was supported by grants TL1TR001443, R01AG047897 and R01AG057751 from the NIH, grant IIR 15-434 from the VA HSR&D, and resources from the San Francisco VA Health Care System.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
2.Bibbins-Domingo
K , Grossman
DC , Curry
SJ ,
et al; US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement.
JAMA. 2016;316(19):1997-2007. doi:
10.1001/jama.2016.15450
PubMedGoogle ScholarCrossref 3.Grundy
SM , Stone
NJ , Bailey
AL ,
et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
J Am Coll Cardiol. 2019;73(24):e285-e350. doi:
10.1016/j.jacc.2018.11.003
PubMedGoogle ScholarCrossref 5.Santos
TRA , Silveira
EA , Pereira
LV , Provin
MP , Lima
DM , Amaral
RG . Potential drug-drug interactions in older adults: a population-based study.
Geriatr Gerontol Int. 2017;17(12):2336-2346. doi:
10.1111/ggi.13070
PubMedGoogle ScholarCrossref 6.Hanlon
JT , Perera
S , Newman
AB ,
et al; Health ABC Study. Potential drug-drug and drug-disease interactions in well-functioning community-dwelling older adults.
J Clin Pharm Ther. 2017;42(2):228-233. doi:
10.1111/jcpt.12502
PubMedGoogle ScholarCrossref 13.Chou
R , Dana
T , Blazina
I , Daeges
M , Jeanne
TL . Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force.
JAMA. 2016;316(19):2008-2024. doi:
10.1001/jama.2015.15629
PubMedGoogle ScholarCrossref 18.Neil
H , Demicco
D , Luo
D ,
et al. Analysis of efficacy and safety in patients aged 65–75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
Diabetes Care. 2006;29(11):2378-2384. doi:
10.2337/dc06-0872
PubMedGoogle ScholarCrossref 19.Knopp
RH , d’Emden
M , Smilde
JG , Pocock
SJ . Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non–Insulin-Dependent Diabetes Mellitus (ASPEN).
Diabetes Care. 2006;29(7):1478-1485. doi:
10.2337/dc05-2415
PubMedGoogle ScholarCrossref 20.Downs
JR , Clearfield
M , Weis
S ,
et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis Prevention Study.
JAMA. 1998;279(20):1615-1622. doi:
10.1001/jama.279.20.1615
PubMedGoogle ScholarCrossref 22.Lee
SJ , Boscardin
WJ , Stijacic-Cenzer
I , Conell-Price
J , O’Brien
S , Walter
LC . Time lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark.
BMJ. 2013;346:e8441. doi:
10.1136/bmj.e8441
PubMedGoogle Scholar 24.Ye
S , Leppin
AL , Chan
AY ,
et al. An informatics approach to implement support for shared decision making for primary prevention statin therapy.
MDM Policy Pract. 2018;3(1):2381468318777752. doi:
10.1177/2381468318777752
PubMedGoogle Scholar 28.Sever
PS , Dahlöf
B , Poulter
NR ,
et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Lancet. 2003;361(9364):1149-1158. doi:
10.1016/S0140-6736(03)12948-0
PubMedGoogle ScholarCrossref 29.Lipsy
RJ . The National Cholesterol Education Program Adult Treatment Panel III guidelines.
J Manag Care Pharm. 2003;9(1)(suppl):2-5.
PubMedGoogle ScholarCrossref 32.Furberg
CD , Adams
HP
Jr , Applegate
WB ,
et al; Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events.
Circulation. 1994;90(4):1679-1687. doi:
10.1161/01.CIR.90.4.1679
PubMedGoogle ScholarCrossref 33.Rosenson
RS , Baker
SK , Jacobson
TA , Kopecky
SL , Parker
BA ; The National Lipid Association’s Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update.
J Clin Lipidol. 2014;8(3)(suppl):S58-S71. doi:
10.1016/j.jacl.2014.03.004
PubMedGoogle ScholarCrossref 34.Rojas-Fernandez
CH , Goldstein
LB , Levey
AI , Taylor
BA , Bittner
V ; The National Lipid Association’s Safety Task Force. An assessment by the Statin Cognitive Safety Task Force: 2014 update.
J Clin Lipidol. 2014;8(3)(suppl):S5-S16. doi:
10.1016/j.jacl.2014.02.013
PubMedGoogle ScholarCrossref 37.Cohen
JD , Brinton
EA , Ito
MK , Jacobson
TA . Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10 138 current and former statin users.
J Clin Lipidol. 2012;6(3):208-215. doi:
10.1016/j.jacl.2012.03.003
PubMedGoogle ScholarCrossref 38.Navar
AM , Peterson
ED , Li
S ,
et al. Prevalence and management of symptoms associated with statin therapy in community practice: insights from the PALM (Patient and Provider Assessment of Lipid Management) Registry.
Circ Cardiovasc Qual Outcomes. 2018;11(3):e004249. doi:
10.1161/CIRCOUTCOMES.117.004249
PubMedGoogle Scholar 41.Mosshammer
D , Lorenz
G , Meznaric
S , Schwarz
J , Muche
R , Mörike
K . Statin use and its association with musculoskeletal symptoms—a cross-sectional study in primary care settings.
Fam Pract. 2009;26(2):88-95. doi:
10.1093/fampra/cmp006
PubMedGoogle ScholarCrossref 45.Newman
CBPD , Preiss
D , Tobert
JA ,
et al; American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin safety and associated adverse events: a scientific statement from the American Heart Association.
Arterioscler Thromb Vasc Biol. 2019;39(2):e38-e81. doi:
10.1161/ATV.0000000000000073
PubMedGoogle ScholarCrossref 46.Gutiérrez-Valencia
M , Izquierdo
M , Cesari
M , Casas-Herrero
Á , Inzitari
M , Martínez-Velilla
N . The relationship between frailty and polypharmacy in older people: A systematic review.
Br J Clin Pharmacol. 2018;84(7):1432-1444. doi:
10.1111/bcp.13590PubMedGoogle ScholarCrossref 47.Herr
M , Robine
JM , Pinot
J , Arvieu
JJ , Ankri
J . Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people.
Pharmacoepidemiol Drug Saf. 2015;24(6):637-646. doi:
10.1002/pds.3772
PubMedGoogle ScholarCrossref 50.Shepherd
J , Blauw
GJ , Murphy
MB ,
et al; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.
Lancet. 2002;360(9346):1623-1630. doi:
10.1016/S0140-6736(02)11600-X
PubMedGoogle ScholarCrossref